Wells Fargo raised the firm’s price target on Cardinal Health (CAH) to $256 from $237 and keeps an Overweight rating on the shares. The firm is also increasing estimates following Q2 results with strong results in all segments. Strength in Pharmaceutical and Specialty remains particularly notable and the first half of 2026 trajectory suggests upside potential in the second half.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAH:
- Cardinal Health price target raised to $255 from $245 at Morgan Stanley
- Cardinal Health price target raised to $252 from $250 at Baird
- Cardinal Health price target raised to $260 from $250 at UBS
- Cardinal Health price target raised to $260 from $250 at Evercore ISI
- Cardinal Health price target raised to $235 from $222 at Mizuho